SCHEMBL8989507

SCHEMBL8989507

Fc1ccc(F)c(-c2nc3occn3c2-c2ccc(Cl)nn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 9/20 0.51
MAP4K4 O95819 9/20 0.51
CSNK1D P48730 8/20 0.51
PRKD2 Q9BZL6 8/20 0.51
MINK1 Q8N4C8 7/20 0.51
MAPK9 P45984 7/20 0.51
GSK3B P49841 6/20 0.47
TAOK1 Q7L7X3 4/20 0.47
EGFR P00533 2/20 0.47
DYRK1A Q13627 2/20 0.47
ERBB2 P04626 1/20 0.47
MARK3 P27448 1/20 0.47
CSNK1A1 P48729 5/20 0.43
CSNK1G2 P78368 5/20 0.43
GSK3A P49840 4/20 0.43
AURKB Q96GD4 2/20 0.43
MAP4K5 Q9Y4K4 2/20 0.43
FGFR1 P11362 1/20 0.43
MAPK13 O15264 5/20 0.36
MAPK8 P45983 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293981 0.91 MAP4K4 (0.61) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4300437 0.89 PRKD3 (0.48) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4301905 0.84 PRKD3 (0.49) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL9057425 0.78 PRKD3 (0.46) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL8989505 0.77 PRKD3 (0.49) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4299359 0.76 MAP4K4 (0.74) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4302719 0.75 MAP4K4 (0.58) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4300811 0.74 PRKD3 (0.41) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4299228 0.72 PRKD3 (0.46) PRKD3MAP4K4CSNK1DPRKD2MINK1
SCHEMBL4307612 0.70 MAP4K4 (0.75) PRKD3MAP4K4CSNK1DPRKD2MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed
WO-2009005675-A1 NOVEL TRIAZOLOPYRIDAZINES ABBOTT LABORATORIES (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270402-A1 Novel triazolopyridazines MAP3K5, MAP3K1, MAP3K2 PRKD3 136/4885MAP4K4 24/4885CSNK1D 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.